Research Advisory Panel
California law, pursuant to Health & Safety Code Sections §11480 & §11481, requires proposed research projects using certain opioid, stimulant, and hallucinogenic drugs classified as Schedule I and Schedule II Controlled Substances as their main study drug(s), to be reviewed and authorized by the Research Advisory Panel of California in the Attorney General's Office. See the Guidelines page for specific criteria.
The Research Advisory Panel primarily seeks to ensure the safety and protection of participating human research subjects and adequate security of the controlled substances used in the study. The Panel Members evaluate the scientific validity of each proposed project, and may reject proposals where the research is poorly conceived, would produce conclusions of little scientific value, or would not justify the exposure of California subjects to the risk of research.
During 2018 the Panel reviewed thirty-nine research study submissions. Thirty-five were approved by the Panel. Among the approved studies, twenty-one studies were Academic research studies, fourteen studies were Multi-Center Clinical Drug Trial research studies.
At the end of 2018 the Panel was monitoring one hundred and thirty-two research projects.
In California, there is not a separate controlled substance license requirement. When the researchers need to apply DEA license/registration, go to the DEA website at www.deadiversion.usdoj.gov, select Form 225 and write N/A in section 4.
Applicants may utilize the DEA Controlled Substance Listings link for further information on controlled substance schedules.